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Conclusions: This is the first study to simultaneously examine the influence of fish oil
supplementation on lipid and thrombogenicity profiles. Our study supports prior evidence
of an improved lipid profile and suggests an enhancement of the anti-platelet effects of
DAPT. Prospective studies are needed to determine the contribution of each of these
effects of fish oil supplementation on thrombotic event occurrence.
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Background: Anti-anginal medications (AAM) directed at lowering the rate pressure
product (RPP) are prescribed to patients undergoing percutaneous coronary intervention
(PCI) for chronic ischemic heart disease (CHD) to reduce repeat revascularization (RR).
Methods: We analyzed the VA VISN17 PCI data from 2008-2011 to evaluate the impact
of AAM score (Table 1) and RPP control on RR.
Results: From 1078 patients, we identified 530 stable angina patients with 12-month
post-PCI follow-up. Mean RPP was 9542.5102.1 (SE) and AAM score 2.810.11
(beta-bockers 96%, calcium channel blockers 36.4%, nitrates 47% and ranolazine 3.4%).
Patients requiring RR had mean AAM score of 3.640.24 and RPP of 9062.9188.7
compared to those without RR (AAM score2.710.14, RPP9472.5120.0; p0.02
for AAM score; p0.07 for RPP comparisons). AAM score2.5 (median) and
RPP9080 (median) were not associated with a lower need for RR (OR for AAM
score0.71, 95% CI: 0.43–1.15, p0.30; OR for RPP0.95, 95% CI: 0.58–1.55,
p0.86, Figure 1), as was a AAM score85th percentile, after adjusting for age, diabetes
mellitus, chronic kidney disease and prior coronary artery disease (OR2.03: 95% CI:
0.99-4.16, p0.06).
Conclusions: Intensive AAM and lowering of RPP alone did not reduce the need for RR
in CHD patients undergoing PCI.
Table 1: Scoring of Anti-Anginal Medical Treatment
Drug Category
(maximum
points/category
 4) Any
ranolazine use
is an additional
1 point. Drug
Low
Dose/
day
(1 point)
Medium
Dose/day
(2 points)
High Dose/
day
(3 points)
Very
High/day
(4 points)
Calcium Channel
Blockers
Amlodipine 5mg 5.0–9.9mg 10mg 10mg
Felodipine 5mg 5.0–9.9mg 10mg 10mg
Isradipine 10mg 10.0–14.9mg 15-19.9mg 19.9mg
Nicardipine 60mg 60–119.9mg 120mg 120mg
Nifedipine 60mg 60–89.9mg 90mg 90mg
Verapamil 240mg 240–359.9mg 360mg 360mg
Diltiazem 240mg 240–359.9mg 360mg 360mg
Beta Blockers Atenolol 50mg 50–99.9mg 100mg 100mg
Bisoprolol 5mg 5–9.9mg 10mg 10mg
Carvedilol 12.5mg 12.5–24.9mg 25–49.9mg 50mg
Labetalol 400mg 400–799.9mg 800mg 800mg
Metoprolol 50mg 50–99.9mg 100–199.9 200mg
Nadolol 80mg 80–159.9mg 160mg 160mg
Nitrates Nitroglycerin
SR
7.5mg 7.51–19.4mg 19.5–39mg 39mg
Nitroglycerin
patch
0.2mg 0.4mg 0.6mg 0.8mg
Isosorbide
dinitrate
60mg 60–89.9mg 90–119mg 119mg
Isosorbide
mononitrate
30mg 60mg 90–119mg 119mg
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Background: We investigated whether statin therapy and high-sensitivity C-reactive
protein (hs-CRP) levels were associated with long term clinical outcomes in acute
myocardial infarction (AMI) patients presenting atrial fibrillation (AF).
Methods: 852 AMI patients (mean age  70.3  12.2 years, 565 males) who were
presented AF on electrocardiogram in arrival at emergency room from the Korean Acute
Myocardial Registry (KAMIR) were divided into two groups; the low hs-CRP group
(hs-CRP  2 mg/dl, n  339, 67.8  12.8 years, 239 males) or the high hs-CRP group
(hs-CRP 2mg/dl, n  513, 71.9  11.5 years, 326 males). We evaluated the incidence
of MACEs during in hospital period and one year clinical follow up according to the statin
therapy in each groups.
Results: Analysis according to level of hs-CRP value of 2.0mg/L, statin treatment had an
effect on reduced the incidence of MACEs in both the low hs-CRP group [statin
group:7.6%, non statin group:14.9%, p0.003] and the high CRP group [statin group:
13.7%, non statin group: 30.2%, p0.001]. In a Cox regression analysis after adjustment
of potential confounder, the statin treatment was a significant predictor of MACEs in low
hs-CRP group [p0.045, HR:0.50,95% CI:0.26-0.98], however in the high hs-CRP
group, statin treatment showed more potent effect on reduction of MACEs risk (p0.001,
HR:0.44, 95% CI:0.29-0.66).
Conclusions: Statin treatment can improve clinical outcome in AMI patients with
presenting AF. These effects were more prominent in patients had high level of hs-CRP,
probably associated with anti-inflammatory effect of statin.
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